Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report

Fusion of the anaplastic lymphoma kinase (ALK) gene is a rare driver in non-small cell lung cancer (NSCLC). Lorlatinib is a third-generation ALK inhibitor approved for the treatment of locally advanced or metastatic ALK(+) NSCLC. The traditional administration method of lorlatinib is whole tablet in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huan, Wu, Zhenyan, Shi, Guangqing, Zhou, Jing, Xiao, Zhenliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644362/
https://www.ncbi.nlm.nih.gov/pubmed/38020308
http://dx.doi.org/10.3892/ol.2023.14113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644362/
https://www.ncbi.nlm.nih.gov/pubmed/38020308
http://dx.doi.org/10.3892/ol.2023.14113

Ejemplares similares